Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

37.18USD
30 Sep 2014
Price Change (% chg)

$-1.21 (-3.15%)
Prev Close
$38.39
Open
$37.00
Day's High
$37.53
Day's Low
$36.26
Volume
771,121
Avg. Vol
319,631
52-wk High
$55.90
52-wk Low
$32.35

SGEN.OQ

Chart for SGEN.OQ

About

Seattle Genetics, Inc. is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin... (more)

Overall

Beta: 1.41
Market Cap (Mil.): $4,739.16
Shares Outstanding (Mil.): 123.45
Dividend: --
Yield (%): --

Financials

  SGEN.OQ Industry Sector
P/E (TTM): -- 128.81 33.98
EPS (TTM): -0.60 -- --
ROI: -19.74 -1.84 17.39
ROE: -31.64 -6.63 18.24
Search Stocks

Seattle Genetics and Takeda's cancer drug meets main trial goal

- Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

29 Sep 2014

UPDATE 1-Seattle Genetics and Takeda's cancer drug meets main trial goal

Sept 29 - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

29 Sep 2014

Seattle Genetics, Takeda's cancer drug meets main goal in trial

Sept 29 - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

29 Sep 2014

Genmab and Seattle Genetics in antibody drug agreement

COPENHAGEN, Sept 10 - Denmark's Genmab will pay Seattle Genetics $11 million to use its technology with Genmab's AXL antibody and future milestones and royalty payments, as a result of a potential product, could amount to $200 million, the companies said on Tuesday.

10 Sep 2014

Seattle mulls creating city ID card to include illegal immigrants

SEATTLE - Seattle lawmakers were considering on Wednesday the creation of a city identification card available to immigrants living in the United States illegally, following the lead of other major U.S. cities including New York and San Francisco.

16 Jul 2014

Competitors

  Price Change
Millennium Pharmacon Internationl Tbk PT (SDPC.JK) Rp. 89.00 -5.00
Eisai Co., Ltd (4523.T) ¥4,418 -17.50
Pfizer Inc. (PFE.N) $29.57 -0.20
Novartis AG (NOVN.VX) CHF90.15 +1.05
Merck & Co., Inc. (MRK.N) $59.28 -0.13
Bayer AG (BAYGn.DE) €95.41 -2.28
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €89.56 +1.95
GlaxoSmithKline plc (GSK.L) 1,413.00p -7.50
Eli Lilly and Co (LLY.N) $64.85 -0.49

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks